Poolbeg Pharma, an infectious disease company spun out of Irish vaccine research firm Open Orphan, has unveiled a “significant breakthrough” in its artificial intelligence (AI) program together with partner OneThree Biotech.
The AI program has now yielded several novel drug targets for the treatment of respiratory syncytial virus (RSV). This is the first time AI has been used to identify disease targets in RSV.
RSV is a common respiratory virus. The virus usually causes mild, cold-like symptoms.
After completing the AI model in June of this year, the OneThree team identified these targets using data from Poolbeg’s unique RSV study data.
Now the companies will identify small molecule inhibitors to effectively treat RSV infection. This includes a number of targets for which there are known drugs with existing Phase I safety and tolerability data.
Phase I trials of a new drug are usually the first phases in which people are involved.
In this final phase of the research plan, OneThree’s AI platform will identify the drugs likely to be most effective against these identified targets with clean safety profiles in RSV patients.
This will speed up a normally lengthy process, with the AI model expected to complete the process in weeks.
Already, the combination of Poolbeg data and OneThree AI platforms has significantly impacted the speed of progress.
“By combining Poolbeg’s data and our ATLANTIS platform, we were able to reach this point in our project in just eight months – significantly faster than a traditional drug discovery project – and we are excited to make significant advances in the treatment of infectious diseases such as RSV” said Neel S. Madhukar, CEO of OneThree Biotech.
Results are now expected before the end of the year.
“This is the first time AI has been used to identify disease targets in RSV and I am pleased to have achieved this significant milestone in the program in such a short time,” said Jeremy Skillington, Chief Executive of Poolbeg Pharma.
“Having identified these novel disease targets, we can now begin the final phase of the program to identify effective drug candidates to treat RSV. Consistent with our low-capital model, this AI-enabled in-silico R&D approach has significantly accelerated the discovery process by having the right partners and expertise to unlock the potential of our unique Human Challenge study data.”
https://www.independent.ie/business/irish/poolbeg-pharma-makes-significant-breakthrough-in-artificial-intelligence-programme-42127081.html Poolbeg Pharma achieves “significant breakthrough” in artificial intelligence program